We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
- Authors
Traverse, Jay H; Henry, Timothy D; Ellis, Stephen G; Pepine, Carl J; Willerson, James T; Zhao, David X M; Forder, John R; Byrne, Barry J; Hatzopoulos, Antonis K; Penn, Marc S; Perin, Emerson C; Baran, Kenneth W; Chambers, Jeffrey; Lambert, Charles; Raveendran, Ganesh; Simon, Daniel I; Vaughan, Douglas E; Simpson, Lara M; Gee, Adrian P; Taylor, Doris A; Cogle, Christopher R; Thomas, James D; Silva, Guilherme V; Jorgenson, Beth C; Olson, Rachel E; Bowman, Sherry; Francescon, Judy; Geither, Carrie; Handberg, Eileen; Smith, Deirdre X; Baraniuk, Sarah; Piller, Linda B; Loghin, Catalin; Aguilar, David; Richman, Sara; Zierold, Claudia; Bettencourt, Judy; Sayre, Shelly L; Vojvodic, Rachel W; Skarlatos, Sonia I; Gordon, David J; Ebert, Ray F; Kwak, Minjung; Moyé, Lemuel A; Simari, Robert D; Cardiovascular Cell Therapy ResearchNetwork
- Abstract
Clinical trial results suggest that intracoronary delivery of autologous bone marrow mononuclear cells (BMCs) may improve left ventricular (LV) function when administered within the first week following myocardial infarction (MI). However, because a substantial number of patients may not present for early cell delivery, the efficacy of autologous BMC delivery 2 to 3 weeks post-MI warrants investigation.
- Publication
JAMA, 2011, Vol 306, Issue 19, p2110
- ISSN
1538-3598
- Publication type
Journal Article
- DOI
10.1001/jama.2011.1670